Intranasal vaccine protects mice against West Nile infection

Researchers from Duke University have developed a nasal vaccine formulation that provides protective immunity against West Nile virus (WNV) infection in mice after only 2 doses. They present their findings at the 2014 American Society for Microbiology Biodefense and Emerging Diseases Research Meeting.

"Our results demonstrate that a needle-free WNV vaccine using only 2 vaccine doses is able to induce protective anti-WNV immunity," says Herman Staats, a researcher on the study. "A nasally-administered, needle-free vaccine able to rapidly induce with minimal per subject would be beneficial for use during WNV outbreaks."

WNV is a mosquito-borne that can cause febrile illness, encephalitis (inflammation of the brain) or meningitis (inflammation of the lining of the brain and spinal cord). Though the virus has been known to be a cause of severe human disease for decades in parts of the Middle-East, Africa, Europe and Australia, it only first appeared in the United States in 1999. It has since spread across the United States and Canada, causing a reported 2,374 cases of infection in people, including 114 deaths in the year 2013 alone, according the Centers for Disease Control and Prevention. While an injectable vaccine based on killed virus is available for horses, there is no vaccine available for humans.

In this study, Staats and his colleagues investigated optimizing the delivery of an antigen-based vaccine for WNV. Most vaccines that use purified protein antigens such as the hepatitis B virus (HBV) vaccine or the (HPV) utilize a total of three immunization to induce protective immunity. In this case, the researchers modified an existing experimental nasal vaccine formulation so that 2 doses of the vaccine administered over 14 days (instead of 3 doses over 21 days) could potentially provide immunity against WNV in mice.

The vaccine formulation was prepared by mixing the antigen and adjuvant compounds in a water based (saline) solution. The vaccine formulation was administered to the mice as nose drops using small volumes of the vaccine. For the 3 doses vaccine formulation, 15 micrograms of the West Nile Virus antigen was combined with the peptide and bacterial DNA adjuvants and administered to mice on day 0, day 7 and day 21. For the 2-dose vaccine, researchers tested both 45 and 60 micrograms of antigen administered on days 0 and 14.

"When mice were infected with West Nile Virus at day 60, the 2-dose vaccine utilizing 60 micrograms of antigen combined with adjuvants protected 100% of mice against morbidity and provided significant protection against weight loss. The 2-dose vaccine regimen using 45 micrograms of antigen combined with adjuvant and the 3-dose vaccine regimen utilizing 15 micrograms of antigen combined with adjuvants provided partial but not significant protection against morbidity or weight loss," says Staats.

Going forward, the researchers are planning future studies in rabbits to continue to develop the intranasal West Nile Virus . Rabbits have a nasal cavity size that is close to the size of the human nasal cavity and therefore is an ideal model to further develop needle-free intranasal vaccines.

Related Stories

The rocky road to a better flu vaccine

Jan 23, 2014

Currently approved flu vaccines are less effective in the elderly, yet an estimated 90% of influenza-related deaths occur in people over 65. A paper published on January 23rd in PLOS Pathogens reports on the ...

Bird vaccine for West Nile Virus

Jul 09, 2013

University of British Columbia researchers have developed a vaccine that may halt the spread of West Nile Virus (WNV) among common and endangered bird species.

Princeton vaccine reaches 90 percent of eligible

Dec 13, 2013

Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Recommended for you

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

Flu vaccine for expectant moms a top priority

Sep 18, 2014

Only about half of all pregnant women in the U.S. get a flu shot each season, leaving thousands of moms-to-be and their babies at increased risk of serious illness.

Experts want restrictions on testosterone drug use (Update)

Sep 17, 2014

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

User comments